These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 12667990)

  • 1. Enzyme therapy of gaucher disease: clinical and biochemical changes during production of and tolerization for neutralizing antibodies.
    Zhao H; Bailey LA; Grabowski GA
    Blood Cells Mol Dis; 2003; 30(1):90-6. PubMed ID: 12667990
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of a panel of highly sensitive, equivalent assays for detection of antibody responses to velaglucerase alfa or imiglucerase enzyme replacement therapy in patients with Gaucher disease.
    Séllos-Moura M; Barzegar S; Pan L; Shi P; Oommen S; Durant J; Ruiz JA
    J Immunol Methods; 2011 Oct; 373(1-2):45-53. PubMed ID: 21846471
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunosurveillance of alglucerase enzyme therapy for Gaucher patients: induction of humoral tolerance in seroconverted patients after repeat administration.
    Rosenberg M; Kingma W; Fitzpatrick MA; Richards SM
    Blood; 1999 Mar; 93(6):2081-8. PubMed ID: 10068682
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enzyme therapy in Gaucher disease type 1: effect of neutralizing antibodies to acid beta-glucosidase.
    Ponce E; Moskovitz J; Grabowski G
    Blood; 1997 Jul; 90(1):43-8. PubMed ID: 9207436
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and efficacy results of switch from imiglucerase to velaglucerase alfa treatment in patients with type 1 Gaucher disease.
    Elstein D; Mehta A; Hughes DA; Giraldo P; Charrow J; Smith L; Shankar SP; Hangartner TN; Kunes Y; Wang N; Crombez E; Zimran A
    Am J Hematol; 2015 Jul; 90(7):592-7. PubMed ID: 25776130
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management of neutralizing antibody to Ceredase in a patient with type 3 Gaucher disease.
    Brady RO; Murray GJ; Oliver KL; Leitman SF; Sneller MC; Fleisher TA; Barton NW
    Pediatrics; 1997 Dec; 100(6):E11. PubMed ID: 9382912
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutation analysis of the acid beta-glucosidase gene in a patient with type 3 Gaucher disease and neutralizing antibody to alglucerase.
    Germain DP; Kaneski CR; Brady RO
    Mutat Res; 2001 Nov; 483(1-2):89-94. PubMed ID: 11600137
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of anti-velaglucerase alfa antibodies in clinical trial-treated patients with Gaucher disease.
    Pastores GM; Turkia HB; Gonzalez DE; Ida H; Tantawy AA; Qin Y; Qiu Y; Dinh Q; Zimran A
    Blood Cells Mol Dis; 2016 Jul; 59():37-43. PubMed ID: 27282565
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative efficacy of dose regimens in enzyme replacement therapy of type I Gaucher disease.
    Altarescu G; Schiffmann R; Parker CC; Moore DF; Kreps C; Brady RO; Barton NW
    Blood Cells Mol Dis; 2000 Aug; 26(4):285-90. PubMed ID: 11042029
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nonprecipitous changes upon withdrawal from imiglucerase for Gaucher disease because of a shortage in supply.
    Zimran A; Altarescu G; Elstein D
    Blood Cells Mol Dis; 2011 Jan; 46(1):111-4. PubMed ID: 20542712
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Safety of use of velaglucerase in 2 patients with type 1 Gaucher's disease].
    Latre P; Giraldo P
    Med Clin (Barc); 2011 Sep; 137 Suppl 1():39-42. PubMed ID: 22230124
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term safety and efficacy of taliglucerase alfa in pediatric Gaucher disease patients who were treatment-naïve or previously treated with imiglucerase.
    Zimran A; Gonzalez-Rodriguez DE; Abrahamov A; Cooper PA; Varughese S; Giraldo P; Petakov M; Tan ES; Chertkoff R
    Blood Cells Mol Dis; 2018 Feb; 68():163-172. PubMed ID: 27839981
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enzyme replacement therapy with taliglucerase alfa: 36-month safety and efficacy results in adult patients with Gaucher disease previously treated with imiglucerase.
    Pastores GM; Shankar SP; Petakov M; Giraldo P; Rosenbaum H; Amato DJ; Szer J; Chertkoff R; Brill-Almon E; Zimran A
    Am J Hematol; 2016 Jul; 91(7):661-5. PubMed ID: 27102949
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical evaluation of chemokine and enzymatic biomarkers of Gaucher disease.
    Deegan PB; Moran MT; McFarlane I; Schofield JP; Boot RG; Aerts JM; Cox TM
    Blood Cells Mol Dis; 2005; 35(2):259-67. PubMed ID: 16125420
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term hematological, visceral, and growth outcomes in children with Gaucher disease type 3 treated with imiglucerase in the International Collaborative Gaucher Group Gaucher Registry.
    El-Beshlawy A; Tylki-Szymanska A; Vellodi A; Belmatoug N; Grabowski GA; Kolodny EH; Batista JL; Cox GF; Mistry PK
    Mol Genet Metab; 2017; 120(1-2):47-56. PubMed ID: 28040394
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enzyme therapy in type 1 Gaucher disease: comparative efficacy of mannose-terminated glucocerebrosidase from natural and recombinant sources.
    Grabowski GA; Barton NW; Pastores G; Dambrosia JM; Banerjee TK; McKee MA; Parker C; Schiffmann R; Hill SC; Brady RO
    Ann Intern Med; 1995 Jan; 122(1):33-9. PubMed ID: 7985893
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Minimal disease activity in Gaucher disease: criteria for definition.
    Di Rocco M; Andria G; Bembi B; Carubbi F; Giona F; Giuffrida G; Linari S; Sibilio M; Spina V; Cappellini MD
    Mol Genet Metab; 2012 Nov; 107(3):521-5. PubMed ID: 22954583
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gaucher's disease: lack of antibody response to intravenous glucocerebrosidase.
    Britton DE; Leinikki PO; Barranger JA; Brady RO
    Life Sci; 1978 Dec; 23(25):2517-9. PubMed ID: 732537
    [No Abstract]   [Full Text] [Related]  

  • 19. [A retrospective study on enzyme replacement therapy in patients with Gaucher disease].
    Duan YL; Zhang YH; Zang Y; Shi HP; Zhang WM; Hu YM
    Zhonghua Er Ke Za Zhi; 2006 Sep; 44(9):653-6. PubMed ID: 17217655
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Velaglucerase alfa for the management of type 1 Gaucher disease.
    Morris JL
    Clin Ther; 2012 Feb; 34(2):259-71. PubMed ID: 22264444
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.